Abivax Shares Rise Midday After a Flurry of Target Revisions
The French biotechnology company's stock is up 2.65% this Thursday, December 18, at midday, amidst a series of target upgrades by international analysts. Following an exceptional year with over 1,200% increase, the stock is benefiting from the enthusiasm surrounding its drug candidate obefazimod, whose Phase 3 results have impressed both markets and financial institutions.
Significant Target Revisions Boost Midday Trading
Abivax has gained 2.65%, reaching 97 euros at midday, marking a recovery after a 15.65% decline over the past seven days. The rebound follows two significant target revisions on December 17 on the American exchange: Leerink Partners raised its target from 115 to 138 dollars while maintaining an outperform rating, and Piper Sandler increased its target from 112 to 142 dollars with an overweight rating. The day before, Citizens also raised its target from 114 to 131 euros while reaffirming its market outperform rating. These adjustments reflect renewed confidence from American brokers in the commercial potential of obefazimod after its presentation at recent medical congresses. Despite recent fluctuations, the stock maintains a spectacular annual performance of 1,234%, reflecting a fundamental revaluation since the positive Phase 3 ABTECT trial results published in July. However, volumes remain low with only 0.02% of capital traded at midday, indicating investor caution.
Abivax Announces Upcoming Presentations at Medical Congress
On December 18, Abivax announced the acceptance of 22 scientific abstracts on obefazimod for presentation at the 21st Congress of the European Crohn's and Colitis Organisation scheduled for February 2026 in Stockholm. These include one oral presentation, five digital oral presentations, and sixteen posters focusing on efficacy, safety, and cytokine evolution data from the Phase 3 ABTECT induction trials. The oral presentation on February 21 will discuss new preclinical antifibrotic data, a serious complication of Crohn's disease characterized by excessive scar tissue formation that often requires surgical intervention. This increase in scientific communications enhances the visibility of Abivax's clinical program within the European medical community, as the company aims to file a marketing authorization application with the FDA in the second half of 2026, pending positive results from the 44-week maintenance trial expected in the second quarter of 2026.
Stock Performance Indicates Sustained Upward Trend
At 97 euros, the stock price is now above the 50-day moving average of 93.11 euros, confirming a sustained upward trend despite the weekly decline. The even greater deviation from the 200-day moving average at 44.80 euros reflects the significant revaluation since January. The RSI is at 36, in a slightly oversold neutral zone, suggesting that the stock has absorbed some of the recent volatility and has technical room before reaching a more pronounced oversold zone. The MACD displays a negative histogram at -1.34, with a MACD line at 1.29 crossing below the signal line at 2.63, indicating a short-term momentum slowdown without invalidating the long-term dynamics. Bollinger Bands frame the stock between a support at 90.61 euros and a resistance at 118.04 euros, with the price currently in the middle of this channel. With a negative beta of -0.14, Abivax maintains almost total decorrelation with the CAC 40, explaining its ability to progress independently in an uncertain market environment.
